-
1 Comment
From a valuation standpoint, the stock is 87.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 169.8.
Based on the above factors, Angion Biomedica Corp. Common Stock gets an overall score of 1/5.
| Industry | Biotechnology |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US03476J1079 |
| Sector | Healthcare |
| Market Cap | 30M |
|---|---|
| PE Ratio | None |
| Target Price | 1.5 |
| Dividend Yield | 0.0% |
| Beta | 0.6 |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ANGN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
